Day: May 3, 2017

Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications

Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications

Current therapeutic approaches to depression fail for millions of patients due to lag in clinical response and non-adherence. Here we provide new support for the antidepressant effect of an anesthetic drug, ketamine, by Inverse-Frequency Analysis of eight million reports from the FDA Adverse Effect Reporting System. The results of the examination of population scale data...

MORE

Popular Blog Posts

The Pandemic, Teen Depression, and Suicide Risk

Ketamine Infusion Therapy for PTSD – Results of an Important New Study

A recent study[1] published in the January 5, 2021 American Journal of Psychiatry by Dr. Adriana Feder and her…

LEARN MORE

Ketamine – The Most Powerful Treatment For Depression Yet Invented

Ketamine continues to gain recognition, by both lay public and medical professionals, as a remarkably effective antidepressant, with minimal…

LEARN MORE

Coronavirus Anxiety Syndrome

Many of our ketamine therapy patients tell us that the COVID-19 pandemic is causing a dramatic increase in their…

LEARN MORE

FDA Approval Expected Monday of Ketamine-derived “Spravato”

      TAKE HOME POINTS: SpravatoTM, a form of ketamine, will be FDA approved on Monday for Treatment…

LEARN MORE

End The Stigma!

Lady Gaga and Bradley Cooper did a masterful remake of “A Star is Born”, now in theaters. We highly…

LEARN MORE